Asia-Pacific Bladder cancer Therapeutics & Diagnostics Market- Segmented by type of cancer and geography (2015-2020)

Published by: | Published Date: January, 2016 | Number of pages: NA

$3,850$7,850

Clear
1.Introduction

1.1 Market Definition

1.2 Research Methodology

1.3 Markets Covered

2. Executive Summary

3. Market Overview

3.1 Market Drivers

3.1.1 Rise in awareness about bladder diseases and their available therapies

3.1.2 Increasing health care expenditure

3.1.3 Innovation in drug development, and subsequent technological advancements

3.2 Market Restraints

3.2.1 Rise in number of patent expirations

3.2.2 Increase in use of generic drugs

3.2.3 Asymptomatic nature of the disease

3.3 Market Opportunitites

3.4 Market Threats

4. Porters Five Force Analysis

4.1 Bargaining Power of suppliers

4.2 Bargaining power of buyers

4.3 Degree of competition

4.4 Threat of substitution

4.5 Threat of new entrants

5. Market Segmentation

5.1 Asia-Pacific Bladder Cancer Therapeutics & Diagnostics Market, by Cancer Type

5.1.1 Transitional Cell Bladder Cancer

5.1.2 Superficial Bladder Cancer

5.1.3 Invasive bladder cancer

5.1.4 Squamous cell bladder cancer

5.1.5 Other rare types

5.2 Asia-Pacific Bladder Cancer Therapeutics Market

5.2.1 Chemotherapy

5.2.2 Immunotherapy

5.2.3 Radiation therapy

5.2.4 Surgery

5.3 Asia-Pacific Bladder Cancer Diagnostics Market

5.3.1 Cystoscopy

5.3.2 Biopsy

5.3.3 Urinalysis

5.3.4 Urine Cytology

5.3.5 Bladder Ultrasound

5.4 Asia-Pacific Bladder Cancer Therapeutics & Diagnostics Market, By Region

5.4.1 China

5.4.2 India

5.4.3 Japan

5.4.4 Australia

5.4.5 Singapore

6. Competitive Landscape

6.1 Mergers & Acquisitions

6.2 Agreements, Collaborations & Partnerships

6.3 New Product Launches

6.4 Recommendations to new market players

7. Company Profiles

7.1 Novartis International AG

7.2 Pfizer Inc

7.3 GlaxoSmithKline plc

7.4 Sanofi S.A

7.5 Eli Lilly and Co

7.6 AstraZeneca plc

7.7 Bristol-Myers Squibb

7.8 F. Hoffmann-La Roche AG

7.9 Celgene Corporation

8. Appendix

8.1. Abbreviations

8.2. Sources

8.3. Bibliography

8.4. Disclaimer
Request Data
Request Data
Request Data
Bladder cancer is a urologic malignancy, arising from the epithelial lining of the urinary bladder. It is the ninth most common cancer worldwide in men and women, with the highest recurrence rate. Though there has been development over the past ten years in bladder cancer treatment, a huge void of unmet needs is yet to be filled. The bladder cancer market is expected to grow modestly from USD 50 million in 2015 at a CAGR of 4-7%.

The Asia-Pacific bladder cancer therapeutics & diagnostic market is segmented based on:

Type
Transitional cell bladder cancer
Invasive bladder cancer
Superficial bladder cancer
Squamous cell bladder cancer
Other rare types
Treatment
Chemotherapy
Immunotherapy
Radiation therapy
Surgery
Major tests
Cystoscopy
Biopsy
Urinalysis
Urine Cytology
Bladder Ultrasound
Geography
Australia
China
India
Japan
Singapore
In Asia-Pacific region, the market for bladder cancer therapeutics & diagnostics is expected to grow due to an increase in awareness and economic status of people, predominantly in the emerging countries like India, China, Japan etc.

Some of the key participants in the industry include Pfizer, GlaxoSmithKline, Sanofi S.A, Roche, Novartis, Eli Lilly and Co, AstraZeneca plc, Bristol-Myers Squibb etc.

Drivers:

Increasing bladder cancer cases
Technological developments
Drug innovations with regard to the bladder cancer
Government initiatives
Rise in aging populace
Advanced health care services
Upsurge in awareness about bladder diseases and their available therapies in the market
Increasing health care expenditure
Restraints:

Rise in the number of patent expirations
Rise in the use of generic drugs
Asymptomatic nature of the disease